Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Public ClinicalTrials.gov record NCT02708680. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety and tolerability of entinostat used in combination with atezolizumab in participants with Advanced Triple Negative Breast Cancer (aTNBC). Additionally, the purpose of the study is to assess how effective entinostat and atezolizumab are in combination in participants with aTNBC.
Study identification
- NCT ID
- NCT02708680
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 89 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2016 (Actual)
- Primary completion
- Mar 31, 2021 (Actual)
- Completion
- Mar 31, 2021 (Actual)
- Last update posted
- Dec 4, 2024
2016 – 2021
United States locations
- U.S. sites
- 19
- U.S. states
- 10
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UAB Comprehensive Cancer Center | Birmingham | Alabama | 35201 | — |
| CBCC Global Research at Comprehensive Blood and Cancer Center | Bakersfield | California | 93309 | — |
| St. Jude Medical Center | Fullerton | California | 92835 | — |
| Los Angeles Hematology Oncology Medical Group | Glendale | California | 91204 | — |
| Torrance Memorial Cancer Care Associates | Redondo Beach | California | 90277 | — |
| SLO Oncology and Hematology Health Center | San Luis Obispo | California | 93401 | — |
| Central Coast Medical Oncology Group | Santa Maria | California | 93454 | — |
| UCLA Hematology/Oncology - Santa Monica | Santa Monica | California | 90404 | — |
| Saint Mary's Regional Cancer Center | Grand Junction | Colorado | 81501 | — |
| Office of Human Research | Hollywood | Florida | 33020 | — |
| Orlando Health, Inc. | Orlando | Florida | 32806 | — |
| Ft. Wayne Hematology and Oncology | Fort Wayne | Indiana | 46804 | — |
| Ft. Wayne Medical Oncology & Hematology, Inc | Fort Wayne | Indiana | 46845 | — |
| Cancer Center of Kansas | Wichita | Kansas | 67214 | — |
| Frauenshuh Cancer Center at Park Nicollet Health Service | Saint Louis Park | Minnesota | 55426 | — |
| Saint Barnabas Medical Cancer Center | Livingston | New Jersey | 07039 | — |
| Hope Women's Cancer Centers | Asheville | North Carolina | 28806 | — |
| Wake Forest Baptist Medical Center | Winston-Salem | North Carolina | 27157 | — |
| Texas Oncology-Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02708680, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 4, 2024 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02708680 live on ClinicalTrials.gov.